Reistone Biopharma’s Pursuit into Ulcerative Colitis Using a – JAK 1 Inhibitor – a Successful Case Study

Time: 3:10 pm
day: Day Two

Details:

  • Describing the latest RSJ10101 results from in UC therapy
  • Defining the drug MOA, clinical endpoints used, and overcoming operational challenges in a UC study
  • Looking forward towards future studies and correlating progress with other disease

Speakers: